Table 2.
Effect of TMTs and the comparison between sorafenib-treated vs sunitinib-treated groups
| Total | Sunitinib | Sorafenib | P-value | |
|---|---|---|---|---|
| Effect on IVC thrombus | ||||
| Change in thrombus height, n (%) | ||||
| Increased | 2 (11.1) | 1 (11.1) | 1 (16.7) | 0.56 |
| Stable | 5 (27.8) | 4 (44.4) | 1 (16.7) | |
| Decreased | 11 (61.1) | 4 (44.4) | 4 (66.7) | |
| Median (range), cm | −0.53 (−4.23 to +1.21) | −0.14 (−1.19 to +1.21) | −0.42 (−2.2 to +0.89) | 0.67 |
| Change in maximum diameter of thrombus, n (%) | ||||
| Increased | 2 (11.1) | 1 (11.1) | 1 (16.7) | 0.79 |
| Stable | 4 (22.2) | 3 (33.3) | 1 (16.7) | |
| Decreased | 12 (66.7) | 5 (55.6) | 4 (66.7) | |
| Median (range), cm | −0.3 (−1.23 to +0.29) | −0.18 (−1.25 to +0.29) | −0.50 (−1.9 to +0.12) | 0.29 |
| Change in thrombus level, n (%) | ||||
| Increased | 0 | 0 | 0 | 0.77 |
| Stable | 14 (77.8) | 8 (88.9) | 5 (83.3) | |
| Decreased | 4 (22.2) | 1 (11.1) | 1 (16.7) | |
| Effect on primitive tumor size, n (%) | ||||
| Increased | 4 (22.2) | 2 (22.2) | 1 (16.7) | 0.57 |
| Stable | 6 (33.3) | 4 (44.4) | 2 (33.3) | |
| Decreased | 8 (44.4) | 3 (33.3) | 3 (50.0) | |
| Median (range), cm | −0.16 (−1.2 to +2.1) | −0.11 (−1 to +2.1) | −0.11 (−1.2 to +0.8) | 0.91 |
| Primitive tumor size before TMT, cm; median (range) | 8.55 (4.9–16.4) | |||
| Thrombus height before TMT, cm; median (range) | 6.97 (2.0–13.8) |
Abbreviations: IVC, inferior vena cava; TMT, targeted molecular therapy.